查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1959910

胜肽類抗生素市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、給藥途徑、分銷管道、地區和競爭格局分類，2021-2031年

Peptide Antibiotics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Route of Administration, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球胜肽類抗生素市場預計將從 2025 年的 53.8 億美元成長到 2031 年的 81.3 億美元，複合年成長率達到 7.12%。

這些抗生素由短的氨基酸序列組成，透過破壞細菌細胞膜或干擾關鍵的細胞內過程發揮抗菌作用。市場成長的主要驅動力是日益嚴重的全球抗生素抗藥性威脅以及對治療多重抗藥性感染疾病的新型有效治療方法的迫切需求。與傳統的小分子藥物不同，肽類抗生素具有獨特的作用機制，且不易誘導抗藥性，這些因素正在推動相關研究的擴展和臨床應用。

市場概覽
預測期 2027-2031
市場規模：2025年 53.8億美元
市場規模：2031年 81.3億美元
複合年成長率：2026-2031年 7.12%
成長最快的細分市場 注射藥物
最大的市場 北美洲

儘管存在這些可能性，但市場擴張仍面臨許多重大障礙，包括代謝穩定性以及大規模合成的高成本。此外，該產業還面臨開發平臺脆弱的問題，限制了後期治療方案的供應。例如，國際藥品製造商協會聯合會（IFPMA）在2025年報告稱，屆時全球臨床研發管線中僅有一種針對重點病原體的抗生素候選藥物處於III期臨床試驗階段。這種缺乏先進候選藥物的情況凸顯了阻礙該領域發展的持續存在的經濟和科學挑戰。

市場促進因素

全球抗菌素抗藥性（AMR）的蔓延是全球胜肽類抗生素市場的主要促進因素。隨著細菌病原體不斷發展出針對標準小分子藥物的防禦機制，人們對具有獨特作用機制的胜肽類療法的需求日益成長。這些藥物對於應對日益增加的一線治療無效感染疾病至關重要。世界衛生組織（WHO）於2025年10月發布的《2025年全球抗菌素抗藥性監測報告》顯示，在2018年至2023年間，超過40%的受監測病原體-抗生素組合的抗藥性增加。這一趨勢凸顯了臨床上迫切需要具有細菌膜破壞特性且抗藥性風險低的胜肽類藥物。世衛組織也報告稱，到2025年，全球六分之一的細菌感染疾病將由抗藥性病原體引起，這表明這些新型治療方法具有巨大的市場潛力。

同時，公私部門對抗生素研發投入的增加，透過降低藥物研發中固有的財務風險，正在加速市場成長。儘管抗生素合成的高成本和有限的商業性回報歷來阻礙了創新，但近期的金融機制正在重振該產業。這些投資使生物技術公司能夠幫助早期胜肽類候選藥物順利度過充滿挑戰的早期臨床試驗階段。正如2025年4月發布的CARB-X 2024會計年度年度報告中所詳述，該加速器支持著67%正在進行的針對重點病原體的非傳統抗菌療法I期臨床試驗計畫。這種資金支持對於穩定開發平臺至關重要，並確保先進的胜肽工程技術能夠轉化為符合嚴格安全標準且具有商業性可行性的治療方法。

市場挑戰

全球胜肽類抗生素市場受到開發平臺脆弱性的嚴重限制，導致後期治療藥物供應不足。這種結構性缺陷源自於抗生素領域持續存在的經濟困境，複雜的胜肽合成過程和高成本往往超過潛在的市場效益。因此，大型製藥公司由於資本投入減少而縮減了業務規模。在此背景下，創新重擔轉移到了中小型生物技術公司身上，而這些公司往往缺乏將新型肽類候選藥物推進到嚴苛且高成本的後期臨床開發階段所需的財務實力。

投資不足的問題因該細分領域藥物研發所需專業科研人才的嚴重短缺而進一步加劇。根據抗菌藥物抗藥性產業聯盟（AMR Industry Alliance）統計，截至2024年，全球整體僅約有3,000名研究人員積極從事新型抗生素的研發工作。這種熟練人才的短缺直接阻礙了代謝穩定性等技術難題的解決，導致新型肽類療法的上市進程延緩，市場成長長期停滯。

市場趨勢

製藥公司和研究機構正擴大利用人工智慧演算法和深度學習模型來預測胜肽結構、最佳化胺基酸序列以降低毒性，並快速識別新型抗菌肽（AMP）。這些技術的融合使得分析傳統方法無法處理的大量生物資料整合為可能，從而有效加速了藥物發現的早期階段。例如，研究人員近期應用機器學習技術，透過對古代生物進行蛋白質體學分析來尋找潛在的治療候選藥物。 2025年8月，賓州大學發表了一篇題為《人工智慧從古代微生物中發現新型抗生素》的論文，報告稱其人工智慧模型成功地從已滅絕物種的基因組中識別出12,623種潛在的抗菌肽，展現了人工智慧能夠揭示的候選物質數量之龐大。

在製造業領域，永續和自動化生產方式正日益普及。特別是，綠色化學溶劑和先進的固相胜肽合成（SPPS）技術的應用旨在減少有害廢棄物並提高規模化生產能力。隨著對胜肽類藥物需求的不斷成長，合約研發生產機構（CDMO）正大力投資自動化基礎設施，以彌合實驗室合成與商業化生產之間的差距。為了順應這一高產能自動化趨勢，產業巨頭正在大幅擴大在歐洲的工廠。例如，在2025年3月發布的題為「CordenPharma將在瑞士新建價值超過5億歐元的胜肽待開發區藥物生產基地」的新聞稿中，CordenPharma宣布建設計畫一座配備先進自動化設備的新工廠，其SPPS反應器的總容量將超過5000公升。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球胜肽類抗生素市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型（非核醣體合成胜肽類抗生素、核醣體合成胜肽類抗生素）
    • 給藥途徑（注射、口服、外用）
    • 分銷通路（醫院藥局、網路藥局、零售藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美胜肽類抗生素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲胜肽類抗生素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區胜肽類抗生素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲胜肽類抗生素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲胜肽類抗生素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球胜肽類抗生素市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Pfizer Inc.
  • Merck & Co., Inc.
  • AbbVie Inc
  • GSK Plc
  • Sandoz International GmbH
  • The Menarini Group
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • AuroMedics Pharma LLC

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 16968

The Global Peptide Antibiotics Market is projected to grow from USD 5.38 Billion in 2025 to USD 8.13 Billion by 2031, achieving a CAGR of 7.12%. These antibiotics are composed of short amino acid sequences that act as antimicrobial agents by disrupting bacterial membranes or interfering with vital intracellular processes. The market's growth is primarily fueled by the increasing global threat of antimicrobial resistance and the critical need for new treatments effective against multi-drug resistant infections. Unlike traditional small-molecule drugs, peptide antibiotics possess unique mechanisms of action and a reduced likelihood of inducing resistance, factors that are driving their expanded research and clinical adoption.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 5.38 Billion
Market Size 2031USD 8.13 Billion
CAGR 2026-20317.12%
Fastest Growing SegmentInjectable
Largest MarketNorth America

Despite this potential, market expansion faces significant hurdles regarding metabolic stability and the high costs associated with large-scale synthesis. The industry also contends with a weak developmental pipeline that restricts the availability of late-stage therapeutic options. For instance, the International Federation of Pharmaceutical Manufacturers and Associations reported in 2025 that the global clinical pipeline included only one antibiotic candidate in Phase III trials aimed at critical priority pathogens. This shortage of advanced candidates emphasizes the enduring economic and scientific challenges that continue to impede the sector's progress.

Market Driver

The rising global prevalence of antimicrobial resistance (AMR) serves as the primary driver for the Global Peptide Antibiotics Market. As bacterial pathogens develop defenses against standard small-molecule drugs, the demand for peptide-based therapeutics with unique modes of action has intensified. These agents are crucial for treating the increasing number of infections that fail to respond to first-line therapies. The World Health Organization's 'Global Antibiotic Resistance Surveillance Report 2025', released in October 2025, noted that resistance increased in over 40% of monitored pathogen-antibiotic combinations between 2018 and 2023. This trend highlights the urgent clinical need for peptides that disrupt bacterial membranes with a lower risk of resistance, while the WHO also reported in 2025 that one in six bacterial infections globally involved resistant pathogens, illustrating the vast market potential for these new interventions.

Concurrently, increased public and private funding for antibiotic R&D is accelerating market growth by alleviating the financial risks inherent in drug development. Although the high costs and limited commercial returns of antibiotic synthesis have historically stifled innovation, recent financial mechanisms have revitalized the industry. These investments allow biotechnology firms to progress early-stage peptide candidates through the difficult initial phases of clinical trials. As stated in CARB-X's '2024 Annual Report' from April 2025, the accelerator has supported 67% of the active Phase 1 clinical pipeline for non-traditional antibacterial therapeutics targeting critical priority pathogens. This financial backing is essential for stabilizing the developmental pipeline and ensuring that advanced peptide engineering technologies can result in commercially viable therapies that meet rigorous safety standards.

Market Challenge

The Global Peptide Antibiotics Market is substantially hindered by a fragile developmental pipeline that limits the supply of late-stage therapeutics. This structural weakness arises from persistent economic difficulties within the antibiotic sector, where the high costs of complex peptide synthesis and clinical trials often outweigh potential market returns. Consequently, capital investment has declined, leading major pharmaceutical companies to reduce their participation. This environment shifts the burden of innovation to smaller biotechnology firms, which frequently lack the financial resilience needed to advance novel peptide candidates through the rigorous and expensive stages of advanced clinical development.

This lack of investment is compounded by a critical shortage of the specialized scientific workforce needed to drive discovery in this niche field. The AMR Industry Alliance reported that in 2024, there were only approximately 3,000 researchers globally actively focused on developing new antibiotics. This scarcity of skilled human capital directly impedes the resolution of technical issues such as metabolic stability, thereby delaying the introduction of new peptide therapies and causing prolonged stagnation in market growth.

Market Trends

Pharmaceutical companies and research institutions are increasingly utilizing AI algorithms and deep learning models to predict peptide structures, optimize amino acid sequences to lower toxicity, and accelerate the identification of novel antimicrobial peptides (AMPs). Integrating this technology enables developers to analyze immense biological datasets that are impossible to process via traditional screening methods, effectively revitalizing the early-stage discovery pipeline. Highlighting this capability, researchers recently applied machine learning to examine the proteomes of ancient organisms for hidden therapeutic candidates. In August 2025, the University of Pennsylvania reported in the article 'AI uncovers new antibiotics in ancient microbes' that their AI model successfully identified 12,623 potential antimicrobial peptides in the genomes of extinct species, demonstrating the vast volume of candidates AI can reveal.

In the manufacturing sector, there is a shift toward sustainable and automated production methods, particularly utilizing green chemistry solvents and advanced Solid-Phase Peptide Synthesis (SPPS) to reduce hazardous waste and enhance scalability. As the demand for peptide therapeutics rises, Contract Development and Manufacturing Organizations are investing heavily in automated infrastructure to bridge the gap between laboratory synthesis and commercial-scale production. Demonstrating this trend toward high-capacity automation, major industry players are significantly expanding their European facilities. For example, CordenPharma announced in a March 2025 press release titled 'CordenPharma Builds >€500m Switzerland Peptide Greenfield Site' its plans to construct a new facility featuring advanced automation with a total SPPS reactor capacity exceeding 5,000 liters.

Key Market Players

  • Pfizer Inc.
  • Merck & Co., Inc.
  • AbbVie Inc
  • GSK Plc
  • Sandoz International GmbH
  • The Menarini Group
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • AuroMedics Pharma LLC

Report Scope

In this report, the Global Peptide Antibiotics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Peptide Antibiotics Market, By Type

  • Non-Ribosomal Synthesized Peptide Antibiotics
  • Ribosomal Synthesized Peptide Antibiotics

Peptide Antibiotics Market, By Route of Administration

  • Injectable
  • Oral
  • Topical

Peptide Antibiotics Market, By Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy & Retail Pharmacy

Peptide Antibiotics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Peptide Antibiotics Market.

Available Customizations:

Global Peptide Antibiotics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Peptide Antibiotics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Non-Ribosomal Synthesized Peptide Antibiotics, Ribosomal Synthesized Peptide Antibiotics)
    • 5.2.2. By Route of Administration (Injectable, Oral, Topical)
    • 5.2.3. By Distribution Channel (Hospital Pharmacy, Online Pharmacy & Retail Pharmacy)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Peptide Antibiotics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Route of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Peptide Antibiotics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Peptide Antibiotics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Peptide Antibiotics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Distribution Channel

7. Europe Peptide Antibiotics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Peptide Antibiotics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Peptide Antibiotics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Peptide Antibiotics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Peptide Antibiotics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Peptide Antibiotics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Peptide Antibiotics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Peptide Antibiotics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Peptide Antibiotics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Peptide Antibiotics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Peptide Antibiotics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Peptide Antibiotics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Peptide Antibiotics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Peptide Antibiotics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Peptide Antibiotics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Peptide Antibiotics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel

10. South America Peptide Antibiotics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Peptide Antibiotics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Peptide Antibiotics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Peptide Antibiotics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Peptide Antibiotics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Pfizer Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Merck & Co., Inc.
  • 15.3. AbbVie Inc
  • 15.4. GSK Plc
  • 15.5. Sandoz International GmbH
  • 15.6. The Menarini Group
  • 15.7. Novartis AG
  • 15.8. Teva Pharmaceutical Industries Ltd.
  • 15.9. AuroMedics Pharma LLC

16. Strategic Recommendations

17. About Us & Disclaimer